Metagenomi Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	44.76	17.2	0.24
Revenue Growth (YoY)	-	160.21%	6978.19%	-
Gross Profit	-	44.76	17.2	0.24
Selling, General & Admin	-	28.85	18.7	9.71
Research & Development	-	94.4	43.14	14.48
Operating Expenses	-	123.25	61.84	24.19
Operating Income	-	-78.49	-44.64	-23.95
Interest Expense / Income	-	0	0.1	0.3
Other Expense / Income	-	-18.26	-3.71	-2.81
Pretax Income	-	-60.23	-41.02	-21.44
Income Tax	-	8.03	2.57	0
Net Income	-	-68.26	-43.59	-21.44
Shares Outstanding (Basic)	21	3	3	3
Shares Outstanding (Diluted)	-	3	3	3
Shares Change	521.79%	0.15%	4.34%	-
EPS (Basic)	-	-20.05	-12.82	-6.58
EPS (Diluted)	-	-20.05	-12.82	-6.58
Free Cash Flow	-	-101.22	15.75	21.35
Free Cash Flow Per Share	-	-29.73	4.63	6.55
Gross Margin	-	100.00%	100.00%	100.00%
Operating Margin	-	-175.38%	-259.53%	-9854.73%
Profit Margin	-	-152.50%	-253.45%	-8823.87%
Free Cash Flow Margin	-	-226.17%	91.55%	8787.65%
EBITDA	-	-51.81	-37.9	-19.82
EBITDA Margin	-	-115.77%	-220.35%	-8154.73%
Depreciation & Amortization	-	8.41	3.03	1.32
EBIT	-	-60.23	-40.93	-21.14
EBIT Margin	-	-134.57%	-237.94%	-8699.59%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).